BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 22036874)

  • 1. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
    Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
    Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.
    Eisenhofer G; Lenders JW; Timmers H; Mannelli M; Grebe SK; Hofbauer LC; Bornstein SR; Tiebel O; Adams K; Bratslavsky G; Linehan WM; Pacak K
    Clin Chem; 2011 Mar; 57(3):411-20. PubMed ID: 21262951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
    Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
    BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
    Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
    Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of utility of SDHB mutation testing in adrenergic metastatic phaeochromocytoma.
    Sue M; Martucci V; Frey F; Lenders JM; Timmers HJ; Peczkowska M; Prejbisz A; Swantje B; Bornstein SR; Arlt W; Fassnacht M; Beuschlein F; Robledo M; Pacak K; Eisenhofer G
    Eur J Endocrinol; 2015 Feb; 172(2):89-95. PubMed ID: 25371406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.
    Rao D; Peitzsch M; Prejbisz A; Hanus K; Fassnacht M; Beuschlein F; Brugger C; Fliedner S; Langton K; Pamporaki C; Gudziol V; Stell A; Januszewicz A; Timmers HJLM; Lenders JWM; Eisenhofer G
    Eur J Endocrinol; 2017 Aug; 177(2):103-113. PubMed ID: 28476870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic pheochromocytoma and paraganglioma.
    Angelousi A; Kassi E; Zografos G; Kaltsas G
    Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations.
    King KS; Prodanov T; Kantorovich V; Fojo T; Hewitt JK; Zacharin M; Wesley R; Lodish M; Raygada M; Gimenez-Roqueplo AP; McCormack S; Eisenhofer G; Milosevic D; Kebebew E; Stratakis CA; Pacak K
    J Clin Oncol; 2011 Nov; 29(31):4137-42. PubMed ID: 21969497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phaeochromocytoma: a catecholamine and oxidative stress disorder.
    Pacak K
    Endocr Regul; 2011 Apr; 45(2):65-90. PubMed ID: 21615192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
    Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
    J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma.
    Peitzsch M; Prejbisz A; Kroiß M; Beuschlein F; Arlt W; Januszewicz A; Siegert G; Eisenhofer G
    Ann Clin Biochem; 2013 Mar; 50(Pt 2):147-55. PubMed ID: 23512172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.
    Pamporaki C; Prodanov T; Meuter L; Berends AMA; Bechmann N; Constantinescu G; Beuschlein F; Remde H; Januszewicz A; Kerstens MN; Timmers HJLM; Taïeb D; Robledo M; Lenders JWM; Pacak K; Eisenhofer G
    Eur J Cancer; 2022 Jul; 169():32-41. PubMed ID: 35500459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
    Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
    Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes
    Andrews KA; Ascher DB; Pires DEV; Barnes DR; Vialard L; Casey RT; Bradshaw N; Adlard J; Aylwin S; Brennan P; Brewer C; Cole T; Cook JA; Davidson R; Donaldson A; Fryer A; Greenhalgh L; Hodgson SV; Irving R; Lalloo F; McConachie M; McConnell VPM; Morrison PJ; Murday V; Park SM; Simpson HL; Snape K; Stewart S; Tomkins SE; Wallis Y; Izatt L; Goudie D; Lindsay RS; Perry CG; Woodward ER; Antoniou AC; Maher ER
    J Med Genet; 2018 Jun; 55(6):384-394. PubMed ID: 29386252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
    Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
    Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma.
    van Berkel A; Lenders JW; Timmers HJ
    Eur J Endocrinol; 2014 Mar; 170(3):R109-19. PubMed ID: 24347425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
    Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
    J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.